Evidence map›Paper›PMID 30915218›Full record

ReviewSAGE open medicine2019

Sepsis: The evolution in definition, pathophysiology, and management.

Bishal Gyawali, Karan Ramakrishna, Amit S Dhamoon

2 registry-linked trialsAbstract readReview
In one paragraph

Review in SAGE open medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 204 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
204citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07436130 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Immunomodulatory Effect of Curcumin in Critically Ill Patients With Sepsis at the Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde": A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

TypeinterventionalSponsorHospital Civil de GuadalajaraRan2026 to 2027Enrolled56ConditionsSepsisArmsCurcumin, Placebo
NCT07655791 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis

TypeinterventionalSponsorAin Shams UniversityRan2026 to 2027Enrolled60ConditionsSepsis - to Reduce Mortality in the Intensive Care UnitArmsNicotinamide 1000 mg
3 · Its place in the literature

Who cites it

204 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

144 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bishal GyawaliDepartment of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Karan RamakrishnaDepartment of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Amit S DhamoonDepartment of Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.ORCID https://orcid.org/0000-0002-2775-8925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been a significant evolution in the definition and management of sepsis over the last three decades. This is driven in part due to the advances made in our understanding of its pathophysiology. There is evidence to show that the manifestations of sepsis can no longer be attributed only to the infectious agent and the immune response it engenders, but also to significant alterations in coagulation, immunosuppression, and organ dysfunction. A revolutionary change in the way we manage sepsis has been the adoption of early goal-directed therapy. This involves the early identification of at-risk patients and prompt treatment with antibiotics, hemodynamic optimization, and appropriate supportive care. This has contributed significantly to the overall improved outcomes with sepsis. Investigation into clinically relevant biomarkers of sepsis are ongoing and have yet to yield effective results. Scoring systems such as the sequential organ failure assessment and Acute Physiology and Chronic Health Evaluation help risk-stratify patients with sepsis. Advances in precision medicine techniques and the development of targeted therapy directed at limiting the excesses of the inflammatory and coagulatory cascades offer potentially viable avenues for future research. This review summarizes the progress made in the diagnosis and management of sepsis over the past two decades and examines promising avenues for future research.

Indexed as

Critical care/emergency medicinehematologyinfectious diseases

Identifiers

PMID30915218
PMCPMC6429642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.